ZIM
RXST icon

Zacks Investment Management’s RxSight RXST Stock Holding History

Zacks Investment Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,830
Closed -$398K – 695
2023
Q2 		$398K Buy
+13,830
New +$308K 0.01% 489

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Zacks Investment Management's RXST Position: Q3 2023 in Review

Zacks Investment Management sold out of RxSight (RXST) in Q3 2023, closing a stake of 13,830 shares — an estimated $398K sold.

Zacks Investment Management first reported a position in RXST in Q2 2023 and held it in 1 quarter. The position peaked at $398K in Q2 2023. 128 funds tracked by Wall St. Rank hold RXST as of Q3 2023.

  • Zacks Investment Management reported no remaining RxSight position as of Q3 2023 after selling out during the quarter.
  • Zacks Investment Management sold 13,830 RxSight shares in Q3 2023, an estimated $398K.
  • Zacks Investment Management first reported a position in RxSight in Q2 2023 and held it in 1 quarter.
  • Zacks Investment Management's RxSight position peaked at $398K in Q2 2023.
  • 128 funds tracked by Wall St. Rank held RxSight as of Q3 2023.

Based on Zacks Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.